High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Inclusion Criteria: * Histologically confirmed stage IIIB/IV NSCLC * Investigator confirmed progression according RECIST 1.1 during previous icotinib treatment * Patients whose tumors: * are EGFR mutation-positive or * T790M mutation-negative * Performance status: WHO 0-2 * Measurable disease according to RECIST 1.1 * at least one measureable lesion .if only one measureable lesion, the biological nature must be confirmed by cytology or histology * a single diameter of lesion could be measured by at least one of the following methods: Chest or abdominal computed tomography(CT)or magnetic resonance imaging(MRI),conventional methods of diameter at least 20mm diameter spiral CT OR at least 10mm * ANC ≥ 1.5\*109/L, Platelets ≥ 75\*109/L, Hgb≥ 9g/dL, Alanine amino transferase ≤ 2 × Upper limit of normal (ULN), Alkaline phosphatase ≤ 2.5 × ULN (\< 5 × ULN if liver metastases), Serum Creatinine ≤ 1.5 × ULN * Women of childbearing age must have a pregnancy test 7 days before treatment and the result were negative ,men of childbearing age: surgical sterilization or treatment during and after the end of three months to take contraceptive measures * Patient must be able to comply with the protocol Exclusion Criteria: * Patient with symptomatic central nervous system metastases * Patient has known active hepatitis B or C, or HIV infection * Pregnant or breastfeeding. * Patient with uncontrolled undercurrent illness or circumstances that could limit compliance with the study